Polaris is meant for patient investors, very positive on the stock: Mehraboon Irani

In a chat with ET Now, Mehraboon Irani, Principal & Head-Private Client Group Business, Nirmal Bang Securities shares his view on Polaris and midcap IT space.

ET Now: Do you like anything from the midcap IT space?

Mehraboon Irani: About 10 days ago when the Polaris deal happened, I mentioned that Polaris is worth at least Rs 225-230. There is still value in Polaris now having gone up 10% today, but this value will take some time to play itself out.

People who bought at Rs 150-160 possibly could come and sell right now. But now, at this present rate, Polaris is meant for patient investors. When the company does its restructuring, getting essentials, it will take at least three to five months.

If you want to participate in this, you need to remain invested in this. At 216 levels, if a person is saying he/she wants to buy Polaris for the next one month, then they are little too late.

Over the last one and one-and-a-half month in the market, money has gone out of defensives and gone into cyclicals. The heroes of pharma space - Sun Pharma and Lupin - have not performed. Same applies to the names like TCS and Wipro. They have not done too many things, but somewhere there is an opportunity.

As far as CNX IT index is concerned, I expect a maximum 3-4% downside, but investors who are feeling stupid of not having bought any front line stocks, have to buy. There is an opportunity somewhere as far as the midcap is concerned. We like Polaris and First Source Ltd. We are very positive on those stocks.